Immunotherapy
E-consult program for immune-related toxicities reduces costs, increases patient access
An electronic consult program for patients who developed endocrine immune-related adverse events has considerably reduced health care utilization.
End-of-life immunotherapy on the rise for patients with metastatic cancer
The percentage of patients with advanced cancers who died within a month of beginning immunotherapy rose significantly in the last decade, study results published in JAMA Oncology showed.
FDA places hold on trial of cell therapy for lung cancer after patient death
The FDA placed a clinical hold on a trial designed to evaluate a novel cell therapy for non-small cell lung cancer after one study participant died.
Safety profiles with immunotherapy similar among older, younger patients with breast cancer
Older patients undergoing immunotherapy for breast cancer experienced similar rates of immune-related adverse events as younger patients, according to a presenter at San Antonio Breast Cancer Symposium.
CAR T-Cell Therapy with Drs. Gottschalk and Velasquez
In this episode, host Shikha Jain, MD, speaks with St. Jude’s Steven Gottschalk, MD, and Paulina Velasquez, MD, about the evolution of bone marrow transplant and cell therapy, increasing accessibility to CAR T-cell therapy and more.
Top food allergy stories of 2023
Food allergy remained a hot topic in 2023. Research focused on early introduction of allergens into infant diets as a prevention strategy, and immunotherapy continued to show success in desensitization.
Top 10 asthma, allergy stories of 2023
Innovation in asthma and allergy care continued in 2023. Healio’s most popular stories this year covered breakthroughs in immunotherapy treatments for food allergy and revised looks at common treatments for congestion and allergy.
First-line immunotherapy benefits patients of all races with NSCLC equally
Survival rates for patients with non-small cell lung cancer treated with first-line immunotherapy did not differ based on race or other socioeconomic determinants, according to a study in National Comprehensive Cancer Network.
VIDEO: Novel agents show 'significant trend' toward better responses for relapsed LBCL
In this video, Brian T. Hill, MD, PhD, discusses research that evaluated the effectiveness of chemo-immunotherapy against three novel combination therapies in the second line or later for patients with relapsed/refractory large B-cell lymphoma.
Multiple myeloma regimens significantly less effective in real-world treatment settings
SAN DIEGO — Standard care treatments for multiple myeloma conferred markedly shorter survival benefits in real-world settings, study results presented at ASH Annual Meeting and Exposition showed.